Alembic Pharma Secures USFDA Approval for Haloperidol Tablets

NEW DELHI — Indian multinational drug manufacturer Alembic Pharmaceuticals Limited has received final regulatory approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP. The clearance opens up a direct pipeline for the company to market generic variants of the established neuroleptic treatment across North American healthcare networks. Production will scale up immediately across the company's vertically integrated manufacturing facilities.

Expanding the Global Generic Central Nervous System Portfolio

The finalized regulatory clearance covers Haloperidol Tablets USP in multiple therapeutic dosage strengths, specifically 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. According to corporate statements, Alembic’s formulation is chemically and therapeutically equivalent to the reference listed drug (RLD), Haldol Tablets, originally developed by Ortho-McNeil Pharmaceutical.

Haloperidol functions as a conventional, first-generation antipsychotic. It is primarily indicated by global medical authorities for managing manifestations of psychotic disorders and controlling motor and vocal tics in both pediatric and adult patients diagnosed with Tourette’s Disorder. By introducing an affordable generic alternative, the drug firm provides healthcare networks with an alternative supply chain to manage volatile prescription costs.

Capturing Valuation in the United States Healthcare Sector

The commercial execution strategy leverages data tracking from industrial market intelligence firms. According to IQVIA data cited in the regulatory announcement, the US market size for Haloperidol Tablets reached an estimated $27 million for the 12 months ending March 2026.

The approval adds to the generic pipeline managed by the company’s international commercialization teams. To date, Alembic has accumulated a total of 240 ANDA approvals from the US health regulator, which includes 221 final approvals and 19 tentative clearances. This established regulatory footprint allows the company to secure consistent shelf space across large American retail pharmacy chains and institutional hospital groups.

Official Sources Section

The material financial metrics, clinical indications, and manufacturing clearances have been verified through statutory corporate disclosures filed directly with the National Stock Exchange of India (NSE) and the BSE Limited. Additional regulatory baselines are governed by standard product registration protocols available via:

• United States Food and Drug Administration (USFDA) Electronic Orange Book

• Alembic Pharmaceuticals Limited Investor Relations Portals

Quote Section

"Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg."

— Corporate Communications Team, official statutory disclosure to Indian equity exchanges

"According to regulatory health bodies, generic equivalency clearances require strict multi-batch dissolution and chemical stability validation to ensure safety profiles map identical paths to the reference listed drug."

— USFDA Evaluation Standards

Why It Matters

For patients, medical professionals, and healthcare providers, the market entry of an additional generic provider helps safeguard against chronic drug shortages that frequently impact older, low-margin generic molecules. For institutional investors tracking the pharmaceutical industry, the final approval underscores Alembic's ability to maintain a steady cadence of generic filings and approvals. This capability supports long-term revenue diversification away from its domestic branded market and strengthens its positioning against intense pricing pressure in the international generics landscape.

Key Facts at a Glance

• Comprehensive Dosage Scope: The regulatory clearance spans five distinct strengths, covering 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg tablets.

• Reference Drug Match: The generic formulation is therapeutically equivalent to original Haldol Tablets by Ortho-McNeil.

• Target Segment Value: The drug holds an estimated annual US market value of $27 million according to recent IQVIA tracking metrics.

• Evolving Approval Pipeline: The milestone raises Alembic's cumulative pool of USFDA ANDA clearances to 240 total items.

FAQ Section

What medical conditions are Haloperidol Tablets used to treat?

Haloperidol is primarily indicated for managing the clinical manifestations of chronic psychotic disorders, as well as controlling involuntary motor tics and vocal utterances in adults and children diagnosed with Tourette's Disorder.

What is the significance of a final ANDA approval from the USFDA?

A final Abbreviated New Drug Application approval indicates that the US health regulator has fully validated the generic drug's manufacturing process, bioequivalence, and safety, allowing immediate commercial sale in the United States.

How large is the market opportunity for this specific drug?

According to IQVIA market intelligence tracking for the rolling 12 months ending March 2026, the addressable US market size for Haloperidol Tablets stands at approximately $27 million.

Where is Alembic Pharmaceuticals headquartered?

Alembic Pharmaceuticals Limited is a vertically integrated global company headquartered in India, with its equities actively traded under ticker symbols on the National Stock Exchange (NSE) and the BSE.

Source: National Stock Exchange of India Corporate Archive, Alembic Pharmaceuticals Limited Regulatory Press Office.